PD-L1 as a Potential Target in Cancer Therapy (Review)
Introduction. Cancer is one of the most serious and common diseases with a high level of mortality. Due to this reason the searching of new directions and methods of cancer treatment is becoming more and more important with each passing year. Significant advances in cancer immunotherapy have been re...
Saved in:
| Main Authors: | N. N. Andrusova, M. A. Kolganova, A. V. Aleshina, I. E. Shohin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2021-02-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/896 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER
by: R. A. Gafanov, et al.
Published: (2018-03-01) -
Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review)
by: K. V. Menshikov, et al.
Published: (2022-10-01) -
The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience
by: Fateen Ata, et al.
Published: (2024-12-01) -
Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence
by: Yuta Yamanaka, et al.
Published: (2024-12-01) -
Production of Antibodies Binding Murine Nuclear PD-L1
by: Valentina Kostenko, et al.
Published: (2024-04-01)